Home
University of Bergen

Martinez lab

Main content

Biorecogniotion group, February 2023

The Martinez & Teigen lab constitutes one of three labs in the Biorecognition group.

The Martinez & Teigen lab studies the relationship between molecular structure and function to understand human health and disease. We use a combination of computational and experimental techniques, within the fields of biophysics, biochemistry and cellular biology. We aim to develop new therapeutic options for inborn errors of metabolism, in particular Phenylketonuria and neurotransmitter disorders (e.g. tyrosine hydroxylase deficiency).

Permanent staff:

Professor Aurora Martinez
Professor Knut Teigen
Ming Ying, chief engineer

News | Research
Bilde av to mus i musemodellen holdt av to personer med blå hansker

A new mouse model gave surprising findings about Folling Disease

A new study from the University in Bergen may shed light on the comorbidities found in adults suffering from this rare disease.

Research project
PRIME logo

New mental health project aims to uncover insulin-related mechanisms linking disorders of body and brain.

An important European-funded initiative has been launched to explore how common molecular mechanisms may link metabolic disorders, especially type 2 diabetes and obesity, with brain disorders such as Alzheimer's disease, obsessive-compulsive disorder, and autism spectrum disorders. Jan Haavik and...

News
graphical abstract mol therapy

From molecule to medicine

Martinez and collaborators are developing a pharmacological chaperone therapy for acute intermittent porphyria

News
Full-length human PAH

The structure of the enzyme implicated in phenylketonuria (PKU)

The structure of full-length phenylalanine hydroxylase in complex with the cofactor BH4 is presented in the most recent issue of PNAS. As the cofactor is also used as a therapy for PKU, this structure is of medical importance.

Research news
Back cover of April 2019 issue of Human Mutation

Novel interaction of the co-chaperone DNAJC12 with phenylalanine hydroxylase variants

Researchers from the lab of Aurora Martinez describe a novel mechanism for the degradation of enzymes involved in phenylketonuria and other neurometabolic disorders.